ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The drug services firm Lonza is getting into the exosome field by acquiring an exosome facility in Massachusetts from Codiak BioSciences and an exosome services unit in Italy from Exosomics. In the deal with Codiak, Lonza will gain access to a perfusion-based process for making exosomes; Codiak will receive $65 million in production services for its clinical-stage drug programs. The deal with Exosomics will give Lonza expertise in exosome analytics and characterization. Exosomes are lipid-membrane-enclosed vesicles secreted by cells that play a role in cell-to-cell communication.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter